Related Experiment Video
Updated: Dec 9, 2025
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
Precision Oncology in Sarcomas: Divide and Conquer
Roberto Carmagnani Pestana1, Roman Groisberg1, Jason Roszik1
1The University of Texas MD Anderson Cancer Center, Houston, TX.
Abstract:
Sarcomas are a heterogeneous group of rare malignancies that exhibit remarkable heterogeneity, with more than 50 subtypes recognized. Advances in next-generation sequencing technology have resulted in the discovery of genetic events in these mesenchymal tumors, which in addition to enhancing understanding of the biology, have opened up avenues for molecularly targeted therapy and immunotherapy. This review focuses on how incorporation of next-generation sequencing has affected drug development in sarcomas and strategies for optimizing precision oncology for these rare cancers. In a significant percentage of soft tissue sarcomas, which represent up to 40% of all sarcomas, specific driver molecular abnormalities have been identified. The challenge to evaluate these mutations across rare cancer subtypes requires the careful characterization of these genetic alterations to further define compelling drivers with therapeutic implications. Novel models of clinical trial design also are needed. This shift would entail sustained efforts by the sarcoma community to move from one-size-fits-all trials, in which all sarcomas are treated similarly, to divide-and-conquer subtype-specific strategies.
Insights
Next-generation sequencing advances sarcoma research, revealing genetic drivers for targeted therapies. Precision oncology requires subtype-specific clinical trials for rare cancers.
Area of Science:
- Oncology
- Genetics
- Drug Development
Background:
- Sarcomas are rare, heterogeneous cancers with over 50 subtypes.
- Next-generation sequencing (NGS) has identified key genetic events in mesenchymal tumors.
- Understanding these genetic alterations is crucial for developing targeted treatments.
Purpose of the Study:
- To review the impact of NGS on sarcoma drug development.
- To discuss strategies for optimizing precision oncology in rare sarcomas.
- To highlight the need for subtype-specific clinical trial designs.
Main Methods:
- Review of current literature on NGS in sarcoma research.
- Analysis of genetic abnormalities in soft tissue sarcomas.
- Discussion of clinical trial design evolution.
Main Results:
- NGS has identified specific driver molecular abnormalities in a significant percentage of soft tissue sarcomas.
- Characterizing these genetic alterations is essential for therapeutic implications.
- Current one-size-fits-all trial models are insufficient for rare sarcoma subtypes.
Conclusions:
- NGS has significantly advanced the understanding of sarcoma biology and treatment potential.
- Optimizing precision oncology requires careful characterization of genetic drivers.
- A shift towards divide-and-conquer, subtype-specific clinical trials is necessary for rare cancer progress.
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:27Tumor Immunotherapy